Fungal biofilm resistance.
Ramage G, Rajendran R, Sherry L, Williams C. · 2012
Read Fungal biofilm resistance. by Ramage G, Rajendran R, Sherry L, Williams C. (2012) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3299327.txt.
Introduction
Ramage, Rajendran, Sherry, and Williams reviewed why fungal infections that grow as biofilms resist treatment, in a 2012 article. A biofilm is a dense community of cells stuck to a surface, common on catheters and other medical devices. Such infections, often caused by the yeast Candida albicans, frequently survive antifungal drugs and end with surgery to remove the infected material.
The authors walk through the many defenses that make biofilms so stubborn. A slimy outer matrix slows drugs down, pump proteins throw drugs out of cells, and a few dormant cells weather attacks and regrow. Crowding, stress responses, and extra copies of drug targets add further layers. Because so many mechanisms stack together, they argue, no single fix is likely to work.
Catalog record
| CREATOR | Ramage G, Rajendran R, Sherry L, Williams C. |
|---|---|
| YEAR | 2012 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 79 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Fungal Biofilm Resistance By Gordon Ramage, Ranjith Rajendran, Leighann Sherry, Craig Williams Published in: International Journal of Microbiology DOI: 10.1155/2012/528521 ABSTRACT Fungal biofilm infections have become increasingly recognised as a significant clinical problem. One of the major reasons behind this is the impact that these have upon treatment, as antifungal therapy often fails and surgical intervention is required. This places a large financial burden on health care providers. This paper aims to illustrate the importance of fungal biofilms, particularly Candida albicans, and discusses some of the key fungal biofilm resistance mechanisms that include, extracellular matrix (ECM), efflux pump activity, persisters, cell density, overexpression of drug targets, stress responses, and the general physiology of the cell. The paper demonstrates the multifaceted nature of fungal biofilm resistance, which encompasses some of the newest data and ideas in the field. 1. CLINICAL SIGNIFICANCE OF FUNGAL BIOFILMS Fungi represent a significant burden of infection to the hospital population. The use of broad-spectrum antibiotics, parenteral nutrition, indwelling catheters, or the presence of immunosuppression, or disruption of mucosal barriers due to surgery, chemotherapy, and radiotherapy are among the most important predisposing factors for invasive fungal infection [1]. Candida bloodstream infection is the third most common cause of nosocomial bacteremia in patients requiring intensive care and the most common etiologic agent of fungal-related biofilm infection. C. albicans, a normal commensal of human mucosal surfaces and opportunistic pathogen in immunocompromised patients, is most frequently associated with biofilm formation. Indwelling medical devices, such as intravascular catheters, can become colonized with Candida spp. allowing the development of adherent biofilm structures from which cells can then detach and cause an acute fungemia and/or disseminated infection. It has recently been shown that the cells that detach from the biofilm have a greater association with mortality than equivalent planktonic yeasts [2]. These implant-associated infections are inherently difficult to resolve and may require both long-term antifungal therapy and the physical removal of the implant to control the infection. Other nonalbicans Candida species associated with biofilm formation and catheter-related bloodstream or device-related infections include C. glabrata, C. parapsilosis, C. dubliniensis, C. krusei, and C. tropicalis [3–5]. Yeasts and filamentous fungi biofilm-related infections have also been increasingly described [6], including Pneumocystis [7], Coccidioides [8], Aspergillus [9], Zygomycetes [10], Blastoschizomyces [11], Saccharomyces [12], Malassezia [13], Trichosporon [14], and Cryptococcus [15]. Cryptococcus neoformans has been shown to colonize and subsequently form biofilms on ventricular shunts [15], peritoneal dialysis fistulas [16], prosthetic hip joints [17], and cardiac valves [18]. Different Trichosporon species can cause disseminated life-threatening infections associated with biofilm-related infections [14, 19, 20], including cardiac grafts [21], catheters [22], and breast implants [23]. Malassezia pachydermatis has been isolated from patients undergoing parenteral nutrition [13], Blastoschizomyces capitatus has been associated with catheter-related fungemia [11], Saccharomyces cerevisiae has been detected from dentures of stomatitis patients [24], and recurrent meningitis has been associated with a Coccidioides immitis biofilm at the tip of a ventriculoperitoneal shunt tubing [8]. There are also growing reports of the filamentous mould Aspergillus fumigatus being involved in biofilm infections. For example, in the respiratory tract, it can cause an aspergilloma, which is a localised infection consisting of a spherical mass of hyphae. Aspergillary bronchitis has also been reported, which is characterized by bronchial casts containing mucus and mycelia [25]. Bronchopulmonary lavage (BAL) of patients with aspergillosis may also reveal the presence of numerous hyphae in the form of a complex multicellular mycetoma structure samples when examined histologically [26]. In addition to this, it has been reported to cause serious biomaterial-related infections of joint replacements, catheters, heart valves, cardiac pace makers, and breast augmentation implants [27–30]. The urinary tract, whilst less frequently associated with A. fumigatus, has been reported to support an aspergilloma [31, 32]. It is also frequently associated with complex sinus infections, which in canines have been described as superficial mucosal fungal plaque [33–36]. It is increasingly clear that a diverse panel of fungi have the capacity to form biofilms, and as such our knowledge of fungal biofilms has improved dramatically. Through work primarily with C. albicans, we now have a clearer perspective on the molecular characteristics of fungal biofilm development [3, 6, 37, 38]. Clinically, these are important as they are refractory to antifungal treatment, which poses a major problem to clinicians as the dose required to eradicate the biofilm can exceed the highest therapeutically attainable concentrations of antibiotics [39]. The focus of this paper is to provide an up-to-date understating of the key factors responsible for the failure of antifungal agents against fungal biofilms. 2. BIOFILM BASICS Microbiologists have historically studied planktonic (free floating and homogeneous cells) in pure culture. However, there has been a paradigm shift as the link between sessile (surface attached and heterogeneous cells) and microbial pathogenesis and human infection is now widely accepted [40]. It is apparent that a wide range of bacteria and fungi are able to alternate between planktonic growth and sessile multicellular communities, commonly referred to as biofilms. Estimates suggest that up to 80% of all microorganisms in the environment exist in biofilm communities [41]. Biofilms are defined as highly structured communities of microorganisms that are either surface associated or attached to one another and are enclosed within a self-produced protective extracellular matrix (ECM) [6]. The advantages to an organism of forming a biofilm include protection from the environment, resistance of physical and chemical stress, metabolic cooperation, and a community-based regulation of gene expression. In recent years, there has been an increased appreciation of the role that fungal biofilms play in human disease as microbes growing within biofilms exhibit unique phenotypic characteristics compared to their planktonic counterpart cells, particularly increased resistance to antimicrobial agents [6]. In addition to providing safe sanctuary for microorganisms, biofilms may also act as reservoirs for persistent sources of infection in a patient and as such adversely effect the health of an increasing number of individuals, including patients with HIV-infection, cancer, transplants, patients requiring surgery or intensive care, and newborn infants [3, 42]. The adhesion and colonization of complex fungal populations onto biological and innate surfaces, such as the oral mucosa or denture acrylic substrates, is commonplace for clinically relevant fungi [43–46]. A wide variety of environmental factors contribute to the initial surface attachment, including the flow of the surrounding medium (urine, blood, saliva, and mucus), pH, temperature, osmolarity, bacteria, presence of antimicrobial agents, and host immune factors [47–52]. Fungal biofilms have defined phases of development that have been described through the use of defined model systems [51, 53–58]. These key phases include arriving at an appropriate substratum, adhesion, colonisation, extracellular matrix (ECM) production, biofilm maturation, and dispersal [37, 55, 59]. Understanding this entire process has enabled us to begin to unravel how some of the mechanisms are involved in resistance. 3. STUDYING FUNGAL BIOFILM RESISTANCE Initial studies that began to investigate biofilm resistance were basic, investigating antifungal effects purely at the phenotypic level through descriptive analyses. The pioneering work by Julia Douglas's group working on C. albicans biofilms utilised some of the earliest models, from which quantitative assessment using dry weight measurements, tetrazolium salt (MTT) reduction assays, and incorporation of [3H] leucine were described [60, 61]. These simple static models were expanded to include flow, which was shown to alter antifungal susceptibility